Ge Healthcare Technologies Inc. ( (GEHC) ) has released its Q1 earnings. Here is a breakdown of the information Ge Healthcare Technologies Inc. presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
GE HealthCare Technologies Inc. is a global leader in healthcare solutions, specializing in medical technology, pharmaceutical diagnostics, and AI-enabled services, with a focus on improving patient care and healthcare efficiency.
In the first quarter of 2025, GE HealthCare reported a 3% increase in revenue year-over-year, with notable growth in the U.S. market. The company also announced a significant acquisition and a $1 billion share repurchase program, highlighting its strategic initiatives and financial strength.
Key financial metrics for the quarter include a net income margin increase to 11.8% from 8.0% the previous year, and a rise in diluted earnings per share to $1.23 from $0.81. However, cash flow from operating activities decreased to $250 million from $419 million year-over-year. The company completed the acquisition of Nihon Medi-Physics, enhancing its radiopharmaceutical capabilities, and launched new products like the Flyrcado™ injection in the U.S.
Looking forward, GE HealthCare maintains its organic revenue growth guidance of 2% to 3% for 2025, despite adjusting its EBIT margin and EPS expectations due to tariff impacts. The company remains focused on innovation and strategic investments to drive long-term value.
Overall, GE HealthCare’s management expresses confidence in its ability to navigate current market challenges while continuing to invest in future growth and innovation.